Wisconsin Investment Partners
Wisconsin Investment Partners (WIP) is an angel investment group based in Madison, Wisconsin. WIP operates a membership model for accredited investors, publishes news and portfolio updates about companies in which WIP or its members have invested, and directs entrepreneurs to apply for investment consideration via the Venture360 platform.
Wisconsin Investment Partners
Services
Angel investing / early-stage capital
Organized group of individual investors that provides capital to early-stage companies through member-driven investments.
Investor membership
Information and onboarding for prospective investor members, including access to WIP dealflow and member activities.
Entrepreneur application via Venture360
Formal application route for entrepreneurs seeking WIP investment, hosted on the Venture360 platform.
Portfolio and news publishing
Public portfolio pages and a news/blog section with updates about portfolio companies, financings, milestones and press coverage.
Angel investing / early-stage capital
Organized group of individual investors that provides capital to early-stage companies through member-driven investments.
Investor membership
Information and onboarding for prospective investor members, including access to WIP dealflow and member activities.
Entrepreneur application via Venture360
Formal application route for entrepreneurs seeking WIP investment, hosted on the Venture360 platform.
Portfolio and news publishing
Public portfolio pages and a news/blog section with updates about portfolio companies, financings, milestones and press coverage.
Portfolio
WIP-published items on SHINE include construction completion of 'Building One' (Feb 13, 2018), delivery of a production accelerator (Oct 18, 2018), and coverage of a $150M financing commitment with Deerfield (Nov 27, 2018). SHINE develops technology to produce Mo-99 without a reactor; site references SHINE patents (e.g., U.S. Patent No. 9,734,926).
#Medical isotopes / nuclear medicine
WIP coverage notes Invenra closed a $7M Series B (Oct 17, 2018) with participation from existing investors including Wisconsin Investment Partners. Invenra develops multispecific/bispecific antibody platforms (B-Body).
#Biotechnology / antibody therapeutics
WIP republishes a Business Wire summary describing a one-year study showing Kiio reduced ED/urgent care visits, opioid prescriptions and low-back-pain-related medical spend when delivered via Quartz Health Solutions (Sept 10, 2018).
#Digital therapeutics / digital health (musculoskeletal care)
WIP republished coverage (Nov 25, 2018) describing FluGen's debt financing of $5.6M and ongoing clinical work on a universal influenza vaccine.
#Biotechnology / vaccines
WIP republishes coverage of BARDA awards and notes Stratatech was acquired by Mallinckrodt in 2016 and received BARDA funding for StrataGraft development.
#Regenerative medicine / human skin tissue
WIP coverage describes delivery of Phoenix's production accelerator to SHINE; Phoenix manufactures compact neutron generators used by SHINE for Mo-99 production.
#Nuclear technology / neutron generators (industrial manufacturer)
WIP-published items on SHINE include construction completion of 'Building One' (Feb 13, 2018), delivery of a production accelerator (Oct 18, 2018), and coverage of a $150M financing commitment with Deerfield (Nov 27, 2018). SHINE develops technology to produce Mo-99 without a reactor; site references SHINE patents (e.g., U.S. Patent No. 9,734,926).
#Medical isotopes / nuclear medicine
WIP coverage notes Invenra closed a $7M Series B (Oct 17, 2018) with participation from existing investors including Wisconsin Investment Partners. Invenra develops multispecific/bispecific antibody platforms (B-Body).
#Biotechnology / antibody therapeutics
WIP republishes a Business Wire summary describing a one-year study showing Kiio reduced ED/urgent care visits, opioid prescriptions and low-back-pain-related medical spend when delivered via Quartz Health Solutions (Sept 10, 2018).
#Digital therapeutics / digital health (musculoskeletal care)
WIP republished coverage (Nov 25, 2018) describing FluGen's debt financing of $5.6M and ongoing clinical work on a universal influenza vaccine.
#Biotechnology / vaccines
WIP republishes coverage of BARDA awards and notes Stratatech was acquired by Mallinckrodt in 2016 and received BARDA funding for StrataGraft development.
#Regenerative medicine / human skin tissue
WIP coverage describes delivery of Phoenix's production accelerator to SHINE; Phoenix manufactures compact neutron generators used by SHINE for Mo-99 production.
#Nuclear technology / neutron generators (industrial manufacturer)